MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$984,098
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from shares sold for ca...
Accounts receivable
Prepaid expenses and deposits
Others
Negative Cash Flow Breakdown
Net loss
Accounts payable and accrued lia...
Operating lease liability
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-11-30
2025-08-31
Net loss
1,597,503
11,911,434
Stock based compensation
74,895
859,494
Depreciation and amortization
16,866
87,825
Impairment loss
-
247,364
Bad debt expense
-
0
Noncash lease expense
7,331
28,027
Unrealized loss on marketable securities
-22,093
-33,714
Lease accretion
1,937
9,047
Accounts receivable
-280,314
213,881
Prepaid expenses and deposits
-256,919
-55,313
Long-term receivables
0
438
Accounts payable and accrued liabilities
-37,613
396,637
Operating lease liability
-9,337
-37,093
Deferred revenue
0
-4,962
Net cash used in operating activities
-984,098
-10,450,387
Short-term investments
-
143,267
Additions to intellectual property
5,099
75,106
Purchase of equipment
0
24,646
Net cash used in investing activities
-5,099
-243,019
Proceeds from exercise of stock options
-
0
Proceeds from shares sold for cash
3,474,051
6,046,163
Proceeds from exercise of warrants
-
0
Net cash provided by financing activities
3,474,051
6,046,163
Effect of exchange rate changes on cash
-5,744
-50,519
Net change in cash for the period
2,479,110
-4,697,762
Cash and cash equivalents at beginning of period
1,802,123
6,499,885
Cash and cash equivalents at end of period
4,281,233
1,802,123
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from shares sold
for cash
$3,474,051
Net cash provided by
financing activities
$3,474,051
Net change in cash
for the period
$2,479,110
Canceled cashflow
$994,941
Accounts receivable
-$280,314
Prepaid expenses and
deposits
-$256,919
Stock based
compensation
$74,895
Unrealized loss on
marketable securities
-$22,093
Depreciation and
amortization
$16,866
Noncash lease expense
$7,331
Lease accretion
$1,937
Net cash used in
operating activities
-$984,098
Effect of exchange rate
changes on cash
-$5,744
Net cash used in
investing activities
-$5,099
Canceled cashflow
$660,355
Net loss
$1,597,503
Additions to intellectual
property
$5,099
Accounts payable and
accrued liabilities
-$37,613
Operating lease liability
-$9,337
Buy us a coffee
Lexaria Bioscience Corp. (LEXXW)
Lexaria Bioscience Corp. (LEXXW)